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A B S T R A C T
Furanocoumarins derived from herbal and citrus extracts can act as antibacterial, antioxidant, im-
munomodulator, apoptotic, and selective anticancer agents, prompting a biological investigation to determine
and predict their clinical therapeutic signiﬁcance. Here, the cell cytotoxic eﬀects of bergapten and xanthotoxin
were analyzed alone and in combination with standard chemotherapeutics on three multidrug resistant cells and
their nonresistant parental counterparts. The furanocoumarins modulatory eﬀects on MDR1, BCRP, and MRP
pump expression and function were investigated. Although quantitative real time PCR demonstrated that the
MDR transcript level changes in a time dependent manner, ﬂow cytometric analyses using ﬂuorescent-labeled
antibodies have indicated that bergapten and xanthotoxin had no signiﬁcant eﬀect on the protein levels. FACS
analyses indicated that these prominent anticancer agents signiﬁcantly blocked MDR1, BCRP, and MRP trans-
porter function. Maximum furanocoumarin-mediated pump activity blockage in the MDR-resistant cells was
quantiﬁed as 87% of normal and consequently, chemotherapeutic accumulation increased up to 2.7-fold and
cytotoxicity tension increased 104-fold. MDR1 eﬄux kinetics also revealed that the maximum velocity and the
pump aﬃnity to daunorubicin were uncompetitively decreased. We conclude that bergapten and xanthotoxin
are cytotoxic agents capable of preventing daunorubicin, mitoxantrone, and cisplatin binding to ABC-trans-
porters and subsequently inhibiting their eﬄux out of cells and they may be a potential combination therapy for
malignant cancers.
1. Introduction
Multidrug resistance (MDR) is one of the major initial obstacles to
successfully treating human malignancies and presents with concurrent
acquired/innate insensitivity to a group of chemotherapeutic agents
(Kondratov et al., 2001). ATP-binding cassette (ABC) transporters be-
long to a large protein superfamily that mediates unidirectional eﬄux
of xenobiotics outside of cells. Current studies have shown that ABC-
transporters play important roles both in cellular protection from var-
ious cytotoxic agents and the occurrence of multidrug resistance in a
wide spectrum of human malignancies (Szakacs et al., 2006). MDR
proteins rapidly pump anticancer drugs out of the MDR-tumor cells,
decrease the intracellular concentration of chemotherapeutics below
their therapeutic thresholds, and often lead to insuﬃcient treatment
(Fletcher et al., 2010). Multidrug resistance associated with BCRP,
MRP, and MDR1 over-expression that extrude mitoxantrone, cisplatin,
and daunorubicin are among the most prevalent occurrence of drug
resistance in many cancers (Gradhand and Kim, 2008).
One of the best approaches for overcoming multidrug resistance is
the use of biochemical compounds, known as MDR modulators or
chemosensitizers, that decrease MDR pump function and/or expression
in tumor cells (Szakacs et al., 2006). Although various chemosensitizers
with diﬀerent toxicities and aﬃnities for ABC-transporters have been
developed, optimal and satisfactory results have not yet been obtained.
Alternatively, high therapeutic concentrations of these modulators in-
crease vital organ toxicity (Riveiro et al., 2010; Tan et al., 2013). Thus,
it is necessary to investigate other compounds with low cytotoxicity at
doses required for MDR pump inhibition. Recently, it has been shown
that natural products, such as fruits and vegetables, contain phyto-
chemicals with potential anticarcinogenic properties and many studies
have been directed at recognizing new compounds with improved
characteristics to circumvent or even work against the various models
of multidrug resistant cancers (Liu, 2003; Colabufo et al., 2010).
Coumarins belong to the benzopyrone families and are active
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components isolated from citrus fruits and vegetables. Over the last
century, coumarin and its derivatives were biologically recognized as
anti-coagulant, anti-microbial, antioxidant, anti-viral, anti-in-
ﬂammatory, HIV-1 integrase inhibitor, enzyme inhibitor, erythroid
diﬀerentiation inducer, and immunomodulator agents, supported by
diﬀerent clinical studies (Riveiro et al., 2010; Thakur et al., 2015).
Nevertheless, this family has also exhibited promising chemother-
apeutic activities at diﬀerent stages of cancer through various me-
chanisms, such as angiogenesis inhibition, antimitotic activity, apop-
tosis initiation, aromatase inhibition, autophagy induction, carbonic
anhydrase inhibition, cell cycle arrest, kinase inhibition, estrogen re-
ceptor modulation, sulfatase inhibition, and topoisomerase blockade.
Due to the former potential applications, extensive eﬀorts have been
made to discover and synthesize coumarin derivatives with improved
antineoplastic activities. Quantitative structure–activity relationship
(QSAR) analyses revealed that diﬀerent moieties in the coumarin nu-
cleus strongly inﬂuence the biological activity of the resulting deriva-
tives. In this regard, several reports have demonstrated that furan
scaﬀolds containing coumarin structures (furanocoumarins) have a
signiﬁcant role in antitumor properties even more than doxorubicin
(Lacy and O'Kennedy, 2004; Lipeeva et al., 2015).
There is accumulating evidence that furanocoumarins eﬀectively
prevent the proliferation of human multidrug resistant tumor cells
(Lacy and O'Kennedy, 2004). Although some synergistic cytotoxicity
has been observed between some furanocoumarins and common che-
motherapeutic agents, little molecular information is available about
their eﬀects on ABC-transporters transcription, translation, or protein
interaction in the multidrug resistant cancers. Therefore, this study was
designed to obtain more information on the modulatory eﬀects of two
furanocoumarin derivatives, bergapten and xanthotoxin, on ABC-
transporter expression and function in human cancer cell lines. This
study oﬀers new perspectives on the development of novel compounds
in the management of multidrug resistant carcinomas.
2. Materials and methods
2.1. Chemicals and media
Bergapten, chemotherapeutic agents (cisplatin, daunorubicin, and
mitoxantrone), indomethacin, novobiocin, verapamil, and xanthotoxin
were purchased from Sigma-Aldrich (Sigma-Aldrich, Deisenhofen,
Germany). RPMI-1640 medium, trypsin, fetal bovine serum (FBS), pe-
nicillin and streptomycin were acquired from Gibco (Grand Island, NY,
USA). BCRP, MDR1, and MRP2 primary antibodies (mouse monoclonal
IgG), goat anti-mouse secondary IgG1 and IgG2a conjugated with FITC,
and the appropriate isotype controls were obtained from Abcam
(Cambridge, USA). All other chemicals and solvents were of analytical
grade and were provided by Merck (Darmstadt, Germany).
2.2. Cell lines, cell culture, and proliferation assay
A2780RCIS (MRP2 overexpressing human epithelial ovarian cancer
cell line), EPG85.257RDB (MDR1 overexpressing human gastric ade-
nocarcinoma cell line), MCF7MX (BCRP overexpressing human epi-
thelial breast cancer cell line), and their parental lines were generously
provided by Professor Herman Lage (University Medicine Berlin,
Charite Campus Mitte, Berlin, Deutschland). Parental A2780,
EPG85.257, and MCF7 cells were cultured in RPMI-1640 medium
supplemented with 10% (v/v) FBS, 2 mM L-glutamine, 100 IU/ml pe-
nicillin, and 100 μg/ml streptomycin in a humidiﬁed CO2 incubator at
37 °C. The media for the RCIS, RDB and MX resistant cell lines was also
supplemented with 33.21 μM cisplatin, 4.74 μM daunorubicin, or
100 nM mitoxantrone, respectively (Lage et al., 2010; Elahian et al.,
2013). Cellular proliferation was determined according to previously
published methods; brieﬂy, 1000 cells were seeded into each well of 96-
well plates. The growth rate was evaluated during a 7-day incubation
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay (Mansouri et al., 2014). All experiments were performed
three independent times in triplicate, and the mean value ± SE was
reported.
2.3. Cytotoxicity analyses and cytotoxicity synergisms
Brieﬂy, the cells were seeded at a density of 1000 cells per well in
tissue culture plates and incubated at 37 °C for 24 h. After, the cells
were treated with various serial dilutions (0–100 μM) of bergapten,
cisplatin, daunorubicin, mitoxantrone, or xanthotoxin. Cell viability
was evaluated after a 5-day incubation of the treated cells using an MTT
assay in the TECAN microplate reader (Inﬁnite®-M200; Grödig, Austria)
at 570 nm. IC10 and IC50 values were deﬁned as the drug concentration
that reduced the surviving fraction of cells in each well by 10 and 50%
compared to the untreated cells, respectively. IC50 and IC10 were cal-
culated from the best regression plot of the percentage viability versus
any drug concentration. Synergistic cytotoxicity was evaluated by the
combined treatment of the cells with various concentrations of the
cisplatin, daunorubicin, or mitoxantrone in the presence of constant
IC10 values of bergapten or xanthotoxin. SIC50 (synergistic IC50) values
were deﬁned as the chemotherapeutic drug concentration that reduced
the surviving fraction of cells in each well by 50% compared to the
untreated cells. The SIC50 was determined from the equation of the
best-ﬁtting regression line plotted from the relative cell viability versus
chemotherapeutic drug concentrations. All experiments were per-
formed three independent times, and the mean values ± SE were re-
ported (Elahian et al., 2013; Mansouri et al., 2014).
2.4. Relative quantiﬁcation of the gene expression
Cells were seeded into 6-well plates at a density of 3 × 105 cells/
well for 24 h. The exponentially growing cells were treated with cell-
speciﬁc IC10 values of bergapten or xanthotoxin for 24, 48, and 72 h.
Approximately 1 × 106 cells were then harvested for total RNA isola-
tion using a highly pure RNA isolation kit (Roche Applied Science,
Mannheim, Germany). One microgram of total RNA was used for re-
verse transcription with the ﬁrst strand cDNA synthesis kit containing
Table 1
IC10 and IC50 values of furanocoumarins and standard chemotherapeutics for the normal and corresponding resistant cells, respectively.
Cell lines Bergapten IC10 ± SEa Xanthotoxin IC10 ± SE Daunorubicin IC50 ± SE Mitoxantrone IC50 ± SE Cisplatin IC50 ± SE
EPG85.257 100 ± 10.17 120 ± 9.70 65.67 ± 1.94 ND ND
EPG85.257RDB 40.29 ± 0.30 21,220 ± 61.51 9063 ± 136.23 ND ND
MCF7 960 ± 92.22 990 ± 30.88 ND 620 ± 23.12 ND
MCF7MX 640 ± 71.90 1.10 ± 0.91 ND 6460 ± 101.77 ND
A2780 4260 ± 131.44 130 ± 11.75 218.54 ± 11.34 ND 1830 ± 185.66
A2780RCIS 80.34 ± 13.87 3521 ± 48.37 210.12 ± 29.78 ND 45,892 ± 1191
Data represent the mean ± standard error of three individual experiments.
ND, not deﬁned.
a Drug concentration (nM) required for 10% or 50% inhibition of cell growth after 5 days of drug exposure.
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random hexamer (Qiagen, Germany). Quantitative real-time analyses
were performed using the 2× QuantiTect SYBR Green PCR kit (Qiagen,
Germany) in a total volume of 20 μl. The following oligonucleotide
primer pairs were used: BCRP (sense 5′–TAT CAA TGG GAT CAT GAA
ACC TGG-3′; antisense 5′–GCG GTG CTC CAT TTA TCA GAA C-3′; an-
nealing 62 °C; NCBI accession: NM_004827.2), MDR1 (sense 5′–CAG
CTA TTC GAA GAG TGG GC-3′; antisense 5′–CCT GAC TCA CCA CAC
CAA TG-3′; annealing 56 °C; NCBI accession: NM_000927.4), MRP1
(sense 5′ –AGA GAC AGC TCA GCA GCT CCT-3′; antisense 5′ –GCC TTG
TCA GCC TCC ATC AG-3′; optimal annealing 59 °C; NCBI accession:
NM_004996.3) MRP2 (sense 5′–CTA CTC CAT CAA TGA TAA TCT GAC
C-3′; antisense 5′–AGG ATG ACA TCA GAA ATA GAG ACC-3′; optimal
annealing 59 °C; NCBI accession: NM_000392.3), and β-actin (sense
5′–TCA TGA AGT GTG ACG TGG ACA TC- 3′; antisense 5′–CAG GAG
GAG CAA TGA TCT TGA TCT- 3′; annealing 60 °C; NCBI accession: NM_
001101.3). Ampliﬁcation was performed using the following para-
meters: pre-denaturation at 95 °C for 10 min; 40 cycles of 15 s at 95 °C,
20 s at annealing temperature and 20 s at 72 °C. Primer eﬃciency was
determined prior to quantiﬁcation. All experiments were run three in-
dependent times in triplicate using the Rotor-Gene Q instrument
(Qiagen, Hilden, Germany) and normalized to β-actin expression in the
respective samples. Relative fold changes in the expression pattern were
quantiﬁed according to the Pfaﬄ method (Elahian et al., 2009).
2.5. Relative quantiﬁcation of protein levels
MDR resistant lines and the parental counterparts were seeded at a
density of 5 × 105 cells/well in 6-well tissue culture plates and in-
cubated at 37 °C for 24 h. The cells were then treated with IC10 con-
centration values of bergapten or xanthotoxin for 24, 48, and 72 h,
followed by trypsinization and washing twice with ice cold PBS. Next,
the cells were ﬁxed and permeabilized for 10 min in 10% v/v room
temperature formaldehyde and 10 min in 90% v/v ice cold methanol.
Subsequently, the cells were blocked for 1 h with 10% (w/v) bovine
serum albumin (BSA) at room temperature to reduce nonspeciﬁc pri-
mary antibody binding. The cells were incubated for 1 h with a mouse
monoclonal antibody directed against either human BCRP, MDR1, or
MRP2 diluted (1:100) in PBS supplemented with 2% bovine serum al-
bumin and 0.01% tween-20 at 4 °C. Then, the cells were treated with
the corresponding FITC-conjugated goat anti-mouse immunoglobulin
(1:100) in the same supplemented PBS buﬀer for 20 min on ice in the
dark. Washing between all steps was performed with PBS at room
temperature with mixing, unless otherwise speciﬁed. The MDR protein
levels were determined using a BD Biosciences FACSCalibur™ ﬂow
cytometer. Cell clumps and cellular debris were excluded from the
analyses using forward/side scatter gating. Cells were excited with a
standard argon laser at 488 nm, and the emission was recorded via a
530/30 nm band-pass ﬁlter (FL1). Appropriate autoﬂuorescence, iso-
type, and secondary antibody controls were also considered to mini-
mize the non-speciﬁc background signals caused by the unsatisfactory
reaction conditions. Flow cytometry data were processed and analyzed
using WinMDI version 2.8. All assays were performed in at least three
independent experiments, and relative protein levels were considered
as the mean ﬂuorescence intensities of treated cells compared to the
untreated controls (Elahian et al., 2009).
2.6. Quantitative kinetics of transporter blockade
ABC-transporter functionality in the presence and absence of se-
lected furanocoumarins was quantiﬁed by ﬂow cytometry. Brieﬂy, cells
were seeded at 5 × 105/well in 6-well plates and were treated with IC10
concentrations of bergapten or xanthotoxin for 24, 48 and 72 h.
Following trypsinization, the cells were resuspended and divided
equally in medium containing MDR ﬂuorescent substrates (daunor-
ubicin for MDR1 and MRP pumps and mitoxantrone for BCRP) alone or
in combination with the corresponding speciﬁc pump inhibitor Ta
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Fig. 1. Relative quantiﬁcations of MRP1, MDR1, and BCRP
transcripts in EPG85.257, MCF7, A2780 and their resistant
counterparts. Cells were incubated with IC10 concentrations
of any furanocoumarins for 24 h, 48 h, and 72 h. Fully
quantitative measurement of mRNA transcripts was con-
ducted using the Pfaﬄ method, and β-actin was used as a
preferred internal control. The results are presented as
mean ± SE of three independent experiments each in tri-
plicate compared with untreated samples. Symbols (***),
(**), and (*) represent the mean diﬀerences between par-
ental and resistant cell transcriptions as P < 0.001,
P < 0.01, and P < 0.05 using one-way ANOVA, respec-
tively.
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(verapamil for MDR1, indomethacin for MRP and novobiocin for
BCRP). After a 30 min incubation period at 37 °C, the cells were har-
vested at 800 ×g and washed twice with ice cold PBS. Then, the cell
suspensions were equally divided again into two fractions and one
portion was placed on ice in the dark for FACS analyses of the accu-
mulation kinetics. The remaining cell portions were treated with com-
plete medium supplemented with (inhibitor treated cells in the accu-
mulation steps) or without (inhibitor free treated cells in the
accumulation steps) their speciﬁc inhibitors. The cells were then in-
cubated at 37 °C for 1 h, washed twice with ice cold PBS, and main-
tained in the dark for FACS analyses for eﬄux kinetic experiments. IC10
values of furanocoumarins were present in all steps of kinetic assays.
Forward/side scatter was used to excluded cell clumps and cellular
debris. Cells were excited with a standard argon laser at 488 nm and the
emission was recorded via a 585/42 nm band-pass ﬁlter (FL2, in the
cases of daunorubicin used as the ﬂuorescent substrate) and 670 nm
long-pass ﬁlter (FL3, for mitoxantrone treated cells). All experiments
were performed at least three independent times, and the cells receiving
no furanocoumarin treatments were used as negative controls. The
following equations represent the mathematical models of the proce-
dure. MFI, modulator, sample, and control are mean ﬂuorescent in-
tensity, inhibitor (verapamil for MDR1, indomethacin for MRP, or no-
vobiocin for BCRP), furanocoumarin treated cells, and untreated cells,
respectively (Elahian et al., 2013; Zhang et al., 2014).
ΔEﬄux = ((MFI(with modulator sample)−MFI(without modulator sample)) ÷
(MFI(with modulator control)−MFI(without modulator control))) × 100%.
=
÷ ×
Drug accumulation (MFI
MFI ) 100%
(without modulator sample)
(without modulator control)
2.7. Statistical analyses
All experiments were performed at least three independent times.
Quantitative data was statistically analyzed using SPSS-22 software.
Diﬀerences between groups were determined by one-way ANOVA with
post hoc Tukey's HSD test, and P-values < 0.05 were considered sta-
tistically signiﬁcant.
3. Results
3.1. Cell proliferation and cytotoxicity assays
Statistical analyses revealed that the maximum speciﬁc growth rate
of the parent lines and their resistant counterparts during the ﬁrst four
days of exponential growth is almost equal (P > 0.05); the parent cell
lines continue logarithmic growth but the resistant cells return to a
stationary phase, which led to a lower biomass (Supplementary Table
S1). Cytotoxicity values of each chemotherapeutic agent and fur-
anocoumarin were calculated from a dose-response curve that was
ﬁtted to the resulting data. All of the data were calculated after 5 days
of exposure using MTT cell viability assays (Supplementary Fig. S1),
and the results of three independent experiments were reported as the
mean ± SE (Table 1). Synergistic cytotoxicity eﬀects of bergapten and
xanthotoxin with any of the chemotherapeutic agents were also calcu-
lated from combination treatments (Table 2, Supplementary Fig. S1).
The data show that both furanocoumarins synergistically increased the
cytotoxicity of cisplatin, daunorubicin, or mitoxantrone in the resistant
cell lines compared to the single standard chemotherapy (P < 0.001).
This phenomenon may be due to the eﬀects of xanthotoxin and ber-
Fig. 2. Quantitative FACS analyses of MDR proteins.
MDR1 and BCRP protein levels of EPG85.257, MCF7, and
their resistant counterparts were quantiﬁed in the pre-
sence of bergapten and xanthotoxin using ﬂow cytometry.
Fold changes were calculated relative to the untreated
conditions for any cells, and the average was calculated
from three independent experiments and graphed as
mean ± SD.
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gapten on the MDR down-regulation and/or physical inhibition of the
ABC eﬄux pump activity.
3.2. MDR pump transcript and protein quantiﬁcation
The relative expression of the BCRP, MDR1, and MRP2 genes in the
presence and absence of IC10 doses of bergapten or xanthotoxin was
assessed using real time PCR. Primer sequences and ampliﬁcation
conditions were optimized to obtain the best ampliﬁcation eﬃciency
(E≥ 1.9 and R-squared≥ 0.95) according to the standard Pfaﬄ
method. BCRP, MDR1, and MRP2 mRNA expression in MCF7MX,
EPG85257RDB, and A2780RCIS were measured at approximately 800-,
310-, and 13-fold more than the transcript contents of their parent
counterparts, respectively. Parent cells showed barely perceptible MDR
transcript level changes after any treatments, because they naturally
produce low levels of any MDR pumps and are classiﬁed as sensitive
cells that lack eﬄux function. MDR1 and MRP1 transcripts represented
few folds of up-regulation time-dependently and BCRP and MRP2 ex-
perienced mild down-regulation in their corresponding resistant cells
after any furanocoumarin treatments. Maximum up- and down- reg-
ulations were recorded near 3-fold from MDR1 and BCRP transcripts
after 48 h and 24 h of both treatments, respectively. Generally MRP1
transcript was less aﬀected after any treatments (Fig. 1). Fig. 2 presents
data acquisition from the ﬂow cytometer and reveals no ABC-trans-
porter protein level changes during the ﬁrst three days after any
treatment with bergapten or xanthotoxin (P > 0.05).
3.3. Furanocoumarins eﬀects on MDR transporter activity
Bergapten- or xanthotoxin-treated parental A2780, EPG85.257, and
MCF7 cells (without any active MDR pumps) did not have a consider-
able stimulatory eﬀect on daunorubicin (for A2780 and EPG cell lines)
or mitoxantrone (for MCF7 cells) accumulation and did not preserve
signiﬁcant eﬀects on MDR pump eﬄux activity over 72 h (P > 0.05)
(Supplementary Fig. S2).
Bergapten and xanthotoxin enhanced daunorubicin accumulation in
A2780RCIS and EPG85.257RDB during the ﬁrst 72 h of exposure
(P < 0.01). Dose-response curves indicate time-dependent involve-
ment of daunorubicin accumulation in both cells (Supplementary Fig.
S3). Maximum daunorubicin accumulation was observed after 24 h and
48 h of drug exposure in A2780RCIS and EPG85.257RDB, respectively
(P < 0.001). Both treatments resulted in a dynamic reduction of MDR1
pump activity in EPG85.257RDB cell lines (Supplementary Fig. S3)
during the ﬁrst three days (P < 0.001). Although MRP-dependent
daunorubicin eﬄux returned to the control rate after 72 h exposure to
xanthotoxin in A2780RCIS cells, drug accumulation increased.
Therefore, the inhibition of oxidoreductase pathways for drug meta-
bolism is the major reason for this phenomenon (Fig. 3 and Supple-
mentary Fig. S3).
Fluorescence intensity values signiﬁcantly increased (P < 0.001)
in bergapten- or xanthotoxin-treated MCF7MX cells in a time dependent
manner. Alternatively, bergapten or xanthotoxin decreased the mitox-
antrone eﬄux in MCF7MX cells after 24 h, 48 h and 72 h (P < 0.001)
Fig. 3. Flow cytometry analyses of furanocoumarin eﬀects on daunorubicin and mitoxantrone eﬄux and accumulation in MDR resistant cells. Cells were pretreated with IC10 con-
centrations of bergapten or xanthotoxin for 24 h, 48 h, and 72 h and then incubated with IC50 values of daunorubicin or mitoxantrone in the presence or absence of a speciﬁc inhibitor
(indomethacin for MRP pump, verapamil for MDR1 pump, or novobiocin for BCRP pump). Eﬄux and accumulation were calculated from the mean intensity of ﬂuorescent che-
motherapeutics and presented as the mean ± SE. The symbols (***), (**), and (*) represent the mean ﬂuorescence diﬀerence between furanocoumarin treated and untreated cells as
P < 0.001, P < 0.05 and P < 0.01, respectively. Con, control; Ber, bergapten; Xan, xanthotoxin.
S.A. Mirzaei et al. Toxicology and Applied Pharmacology 337 (2017) 22–29
27
(Fig. 3 and Supplementary Fig. S4).
4. Discussion
The literature shows that many neutral and synthetic coumarins are
signiﬁcant cancer cell growth inhibitors in vitro and in vivo. Coumarin
derivatives participate in cell death through inhibition of cellular pro-
liferation cascades and activation of regulatory and apoptotic proteins
(Jun et al., 2014). Studies have shown that a substituent on C3, C4, C7
and C8 of the coumarin core structure with amide, hydrazide, aryl and
imine groups has a deﬁnite role in selective antitumor activity (Emami
and Dadashpour, 2015). Therefore, furanocoumarins are more potent
antioxidant, immunomodulatory, cytotoxic, and cytostatic agents and
growth modulators (Piao et al., 2004; Finn et al., 2005; Pingaewa et al.,
2014).
Unfortunately, overexpression of ABC-transporters encoded by
multidrug resistance genes are among the major obstacles for successful
cancer chemotherapy (Szakacs et al., 2006). In this regard, natural
coumarins in combination with common chemotherapeutic agents
provide increased drug bioavailability by interfering with drug meta-
bolism and ABC-transporters and strong synergistic interactions against
multi drug resistant cancer cells (Kimura et al., 2005; Eﬀerth and Volm,
2017). Previously, bergaptol, bergapten and bergamottin, as famous
furanocoumarins in grapefruit juice, have increased the steady-state
uptake of vinblastine in the cells. The mechanisms conferring these
capabilities may include direct interaction of the drugs with MDR pump
expression and function (Ohnishi et al., 2000) or enhanced cytotoxicity
using the elimination of oxidoreduction enzyme cascades (Elahian
et al., 2014; Elahian et al., 2016). Consistent with other studies, the
results described in Tables 1 and 2 conﬁrmed that cisplatin, daunor-
ubicin, or mitoxantrone cytotoxicity was remarkably increased in the
most resistant cancer cells treated with non-toxic concentrations of
xanthotoxin and bergapten.
Although some ﬂuctuations were observed in BCRP, MDR1, and
MRP gene expression in the parental and resistant cell lines during the
examination time, the gene expressions almost returned to a steady
state level after 72 h of drug exposure (Fig. 1). Alteration in the activity
and expression of ABC-transporters seems to be a primary cell response,
necessary for xenobiotic detoxiﬁcation and adaptation processes
(Fromm, 2002; Fromm, 2004). A few fold change in transcript levels
(non-signiﬁcant with P > 0.05) have also been previously reported for
similar compounds (Hsieh et al., 2014); our results again demonstrated
diversity in furanocoumarins eﬀects on MDR gene expression and
protein levels, which are most likely cell and even pump speciﬁc (Zhao
et al., 1993; Canitrot et al., 1998; Pulaski et al., 2005).
Alternatively, bergapten and xanthotoxin enhanced intracellular
daunorubicin or mitoxantrone accumulation in the resistant cancer cell
lines. Since MDR protein levels were not signiﬁcantly changed in the
presence of the furanocoumarins, we concluded that the stimulatory
eﬀect of bergapten and xanthotoxin on cellular chemotherapeutic agent
accumulation was due to their inhibitory eﬀects on MDR1, BCRP, and
MRP functions. These data are consistent with cytotoxicity; when the
bergapten limited the MDR1 pump activity to 47% of untreated cells,
daunorubicin accumulation increased 116% in this cell type and
EPG85.257RDB sensitivity to daunorubicin toxicity increased 102-fold.
A2780RCIS cells were 48-fold more sensitive to cisplatin and drug ac-
cumulation increased 269% when furanocoumarins decreased the ef-
ﬂux activity 13%. Upon transient exposure of MCF7MX cells to fur-
anocoumarins, a parallel increase in mitoxantrone cytotoxicity up to 2-
fold and mitoxantrone eﬄux reduction of approximately 71% of normal
occurred (Tables 1, 2 and Fig. 3). Although in some cases the eﬄux
activity returned to normal after 72 h of furanocoumarins treatment,
the chemotherapeutic agent accumulation followed an ascending trend
(Fig. 3). The mechanism conferring this enhanced bioavailability may
include inhibition of intercellular oxidoreduction and degradation of
daunorubicin and mitoxantrone via inhibition of CYP3A and CYP1A1/2
enzymatic activities in the catalyst of phase I and phase II drug bio-
transformation. Obviously, these small molecules may also inhibit cy-
tochrome enzyme activity directly through binding to them, which may
also be useful for cancer treatment (Wen et al., 2002; Kim et al., 2014).
The results suggested that bergapten and xanthotoxin act as ABC-
transporter inhibitors and the presumable underlying mechanism of their
inhibitory eﬀect could be derived from their ability to interact with ABC-
transporters and interfere with the eﬄux activity, increasing the in-
tracellular drug accumulation (Nabekura, 2010). Consistent with our
observation, previous studies have shown that cnidiadin, bergamottin,
and psoralen increase the bioavailability and accumulation of MDR1
substrates by partially inhibiting transporter activity (Ohnishi et al., 2000;
Honda et al., 2004). Previously, several natural compounds have been
deﬁned as MDR transporter competitive or uncompetitive blockers as
they occupy the drug binding sites or block the ATP hydrolysis process in
MDR pumps (Safa, 2004; Marchetti et al., 2007). MDR1 pump kinetic
analyses here showed a potent interaction of the furanocoumarins with
daunorubicin, accumulating the chemotherapeutic agent in the MDR
cells, inhibiting growth, and causing cell death. Kinetic analyses revealed
that the maximum velocity of eﬄux (Vmax) and the MDR1 aﬃnity to
daunorubicin (Km) were signiﬁcantly decreased in the EPG85.257RDB
cells (P < 0.001) treated with bergapten (Vmax = 23.68 ± 0.58 μM/
min and Km= 2.24 ± 0.64 μM) or xanthotoxin (Vmax = 12.94 ±
1.14 μM/min and Km= 1.60 ± 0.91 μM). Even the normal Vmax and
Km for the MDR1 pump were calculated to be 66.24 ± 5.90 μM/min
and 6.73 ± 0.70 μM, respectively, thus, representing uncompetitive in-
hibition on MDR1 (Erzengin et al., 2012).
Finally, some controversies in the accumulation and eﬄux results in
furanocoumarin-treated parental cells are mainly due to the absence of
a sophisticated eﬄux pump in these cells and probable activation of
parser compounds in the cells, activation of degradation pathways, the
existence of a variety of nonspeciﬁc pumps on parental cells that are
involved in xenobiotic transportation out/in, or the expression of some
members of organ anion dependent families that can reduce the in-
tracellular concentration of chemotherapeutic agents (Albertus and
Laine, 2001; Deeley et al., 2006).
5. Conclusion
Our results convincingly demonstrated that selected fur-
anocoumarins are capable of uncompetitively impeding the binding and
eﬄux of chemotherapeutic agents by ABC-transporters. Since one of the
main causes of failure in chemotherapy is related to inherent or ac-
quired drug resistance due to over expression of eﬄux pumps by tumor
cells, the potency of bergapten and xanthotoxin in reversing drug eﬄux
would make these components potential candidates in clinical studies
in future.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.taap.2017.10.018.
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